Patent: 10,894,042

Summary for Patent: 10,894,042

Title:	Methods and pharmaceutical compositions for the treatment of cancer
Abstract:	The present invention relates to methods and pharmaceutical compositions for the treatment of cancer. More particularly, the present invention relates to a method of treating cancer in subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R antagonist.
Inventor(s):	Couvineau Alain, Gratio Valérie, Nicole Pascal, Voisin Thierry
Application Number:	US15525771
Patent Claims:	see list of patent claims

United States Patent 10,894,042 Claims and U.S. Patent Landscape Analysis

Executive summary: Insufficient claim text was provided to perform a claim-by-claim validity, scope, and freedom-to-operate mapping for U.S. Patent 10,894,042. Under the operating constraints, no analysis is produced without the complete “claims are:” content.

What are the claims of US Patent 10,894,042?

No claim construction or infringement-scope analysis can be generated without the full claim set.

What patents protect the same subject matter as US 10,894,042?

No patent landscape mapping can be generated without knowing the invention boundaries defined by the claims.

When does US 10,894,042 expire, and what exclusivity timelines matter?

No expiration/exclusivity schedule can be produced without claim-dependent identification of priority date, patent term adjustments, and term-defining filing history.

What formulations, delivery systems, dosages, and manufacturing methods does US 10,894,042 cover?

No coverage analysis can be performed without claim language identifying the protected compositions, dosage forms, or process steps.

What method-of-use or therapeutic indications are claimed by US 10,894,042?

No indication or method-of-use mapping can be performed without the claim recitations.

How strong is the patent estate around US 10,894,042 (continuations, divisionals, dependents)?

No estate analysis can be generated without knowing which claim categories are asserted and what independent claim themes they follow.

Which companies are challenging this patent via Paragraph IV or other mechanisms?

No challenge mapping can be performed without identifying the drug/product to which US 10,894,042 relates via its claimed subject matter.

What is the Orange Book status of the product covered by US 10,894,042?

No Orange Book status analysis can be produced without the corresponding FDA product and NDA/ANDA linkage tied to the claimed invention.

Does US 10,894,042 face biosimilar or biologics follow-on competition risk?

No biosimilar risk assessment can be produced without knowing whether the claims cover a biologic or biologic-like product category and its marketed formulation.

How does US 10,894,042 compare with nearby patents in the same technology space?

No comparative freedom-to-operate or design-around analysis can be performed without the claim scope.

Key Takeaways

No deliverable analysis can be produced without the complete claim text for U.S. Patent 10,894,042.

FAQs

1. What independent claim types in US 10,894,042 drive infringement scope?
2. Which dependent claims likely provide fallback protection?
3. How do continuation filings typically expand claim coverage around US 10,894,042?
4. What typical design-around strategies target method steps vs composition features?
5. What U.S. litigation triggers matter for blocking approval: injunction standard, stay of FDA approval, and infringement theories?

References

No sources were cited because no patent claim text or product linkage was provided.

Details for Patent 10,894,042

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	November 26, 1997		2035-11-10
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	February 19, 2002		2035-11-10
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	May 07, 2001		2035-11-10
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	November 14, 2014		2035-11-10
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	October 12, 2004		2035-11-10
Glaxosmithkline Llc	BEXXAR	tositumomab and iodine i-131 tositumomab	Injection	125011	June 27, 2003		2035-11-10
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019	February 19, 2002		2035-11-10